Want to see KR:033270 full AI Analyst Report?

KOREA UNITED PHARM, INC. (033270) Price & Analysis

― Followers

033270 Stock Chart & Stats

₩16850.00

₩90.00(0.54%)

Oct 29, 2026

―

Day’s Range― - ―

52-Week Range₩16,100.00 - ₩21,800.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)29.74K

Market Cap

₩244.48B

Enterprise Value₩113.07B

Total Cash (Recent Filing)₩178.56B

Total Debt (Recent Filing)₩14.86B

Price to Earnings (P/E)3.4

Beta0.05

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.62%

Share Statistics

EPS (TTM)4922.11

Shares Outstanding15,910,775

10 Day Avg. Volume38,256

30 Day Avg. Volume29,744

Financial Highlights & Ratios

PEG Ratio0.39

Price to Book (P/B)0.69

Price to Sales (P/S)1.08

P/FCF Ratio11.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)2,966

Revenue Forecast (FY)₩303.50B

Bulls Say, Bears Say

Bulls Say

Very Low LeverageVery low leverage gives the company substantial financial resilience and flexibility. Limited debt obligations reduce pressure on earnings and cash flow, while preserving capacity to fund pharmaceutical development, sustain operations, and respond to changing market conditions over the next several quarters.

Improving ProfitabilityThe sharp improvement in net and operating margins indicates stronger recent earnings power and better profitability from the existing pharmaceutical business. If maintained, this provides more internal funding for product development, commercial activity, and shareholder returns while strengthening competitive resilience.

Strong Operating Cash FlowOperating cash flow exceeding reported net income supports the quality of recent earnings and demonstrates effective cash generation from ongoing operations. This strengthens the company’s ability to finance working needs and investment internally, reducing reliance on external funding despite some free-cash-flow variability.

Bears Say

Free Cash Flow InconsistencyOnly about half of reported earnings converted into free cash flow in the TTM period, and prior results included notably weak free cash flow. This inconsistency can limit dependable funding for development, expansion, and distributions, making the company’s cash-generation profile less predictable.

Margin VolatilityAlthough current margins are strong, the substantial movement across years raises questions about how durable the improvement is. Results may reflect changing product mix, one-off effects, or cyclical influences, which could make future earnings less stable than the latest period alone suggests.

Uneven Revenue MomentumRecent revenue growth is positive but modest, and the historical pattern is described as moderate and uneven. This indicates that sustained expansion in demand, product adoption, or market reach is not yet consistently demonstrated, potentially limiting operating leverage and long-term growth visibility.

033270 FAQ

What was KOREA UNITED PHARM, INC.’s price range in the past 12 months?

KOREA UNITED PHARM, INC. lowest stock price was ₩16100.00 and its highest was ₩21800.00 in the past 12 months.

What is KOREA UNITED PHARM, INC.’s market cap?

KOREA UNITED PHARM, INC.’s market cap is ₩244.48B.

When is KOREA UNITED PHARM, INC.’s upcoming earnings report date?

KOREA UNITED PHARM, INC.’s upcoming earnings report date is Nov 18, 2026 which is in 19 days.

How were KOREA UNITED PHARM, INC.’s earnings last quarter?

KOREA UNITED PHARM, INC. released its earnings results on Aug 14, 2026. The company reported ₩2377.304 earnings per share for the quarter.

Is KOREA UNITED PHARM, INC. overvalued?

According to Wall Street analysts KOREA UNITED PHARM, INC.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does KOREA UNITED PHARM, INC. pay dividends?

KOREA UNITED PHARM, INC. pays a Annually dividend of ₩610 which represents an annual dividend yield of 3.62%. See more information on KOREA UNITED PHARM, INC. dividends here

What is KOREA UNITED PHARM, INC.’s EPS estimate?

KOREA UNITED PHARM, INC.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KOREA UNITED PHARM, INC. have?

KOREA UNITED PHARM, INC. has 15,910,775 shares outstanding.

What happened to KOREA UNITED PHARM, INC.’s price movement after its last earnings report?

KOREA UNITED PHARM, INC. reported an EPS of ₩2377.304 in its last earnings report. Following the earnings report the stock price went up 1.046%.

Which hedge fund is a major shareholder of KOREA UNITED PHARM, INC.?

Currently, no hedge funds are holding shares in KR:033270

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KOREA UNITED PHARM, INC.

Korea United Pharm Inc. is a South Korean enterprise dedicated to the development, production, and distribution of a wide array of pharmaceutical products. The company's extensive portfolio encompasses therapeutic solutions for various medical fields, such as the respiratory, musculoskeletal, gastrointestinal, cardiovascular, and central nervous systems, in addition to treatments for cancer, infections, allergies, and immune disorders. It also supplies over-the-counter drugs. Founded in 1987, Korea United Pharm Inc. is headquartered in Seoul, South Korea.